Actinium Pharmaceuticals Announces Product Showcase and Other Visibility Extending Activities at the BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations
February 20, 2018 07:30 ET
|
Actinium Pharmaceuticals
Actimab-MDS to be featured in a Product Theater on February 21st Members of Actinium’s executive and clinical development teams to participate in conference activities and extend the visibility of...
Actinium Announces Submission of IND For Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML
February 12, 2018 16:15 ET
|
Actinium Pharmaceuticals
• Conference call to be held on Tuesday, February 13th, 2018 at 4:30 PM ET to discuss planned Phase 1 clinical trial with Dr. Ehab Atallah • New trial represents expansion of Actinium’s CD33 program...
Actinium Pharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record
February 12, 2018 07:30 ET
|
Actinium Pharmaceuticals
• To be a shareholder of record, investors are advised to own Actinium stock by 4:00 PM ET, Monday, February 12, 2018 to account for T+2 settlement timing • Actinium’s executive management and...
Actinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on Myeloablation
February 08, 2018 08:00 ET
|
Actinium Pharmaceuticals
- Mr. Kapur joins Actinium with more than two decades of biopharmaceutical commercial experience at Johnson & Johnson, BAXALTA and Bristol-Myers Squibb - Global leader with deep expertise in...
Actinium Pharmaceuticals Reminds Investors of Record Date for Rights Offering
February 07, 2018 09:00 ET
|
Actinium Pharmaceuticals
- Record date established as February 14, 2018 - To be a shareholder of record, investors are advised to own Actinium stock by 4:00 PM ET, Monday, February 12, 2018 to account for T+2 settlement...
Actinium Pharmaceuticals Announces Trial to Study Actimab-A in Combination with CLAG-M for Relapsed or Refractory AML Patients
February 06, 2018 07:30 ET
|
Actinium Pharmaceuticals
- Actimab-A plus CLAG-M further expands Actinium’s CD33 program and addressable patient population of Actimab-A - Combination aligns with Actinium’s focus on improving bone marrow transplant access...
Actinium Pharmaceuticals to Present at the BIO CEO & Investor Conference
February 05, 2018 16:15 ET
|
Actinium Pharmaceuticals
NEW YORK, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced today that it will be attending and presenting at the BIO CEO...
Actinium Pharmaceuticals Announces Rights Offering
February 01, 2018 16:05 ET
|
Actinium Pharmaceuticals
NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced today that it has filed a preliminary prospectus supplement as...
Actinium Pharmaceuticals Announces Acceptance of Abstract for AACR Annual Meeting Highlighting Superior In Vivo Survival Data for Actinium Labelled Daratumumab Versus Unlabeled Daratumumab, A Blockbuster Product
February 01, 2018 07:30 ET
|
Actinium Pharmaceuticals
- Poster to present additional data showcasing ability of Actinium’s AWE Technology to yield a potential biobetter of daratumumab, a blockbuster CD38 targeted therapy for multiple myeloma NEW YORK,...
Actinium Pharmaceuticals Issues Letter to Investors Providing Company Update and Outlook for 2018
January 25, 2018 08:00 ET
|
Actinium Pharmaceuticals
Strong finish to 2017 sets stage for series of value enhancing milestones in 2018 NEW YORK, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the...